Skip to search formSkip to main contentSkip to account menu

tideglusib

Known as: 4-Benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

NP 031112

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis
Tideglusib®, a GSK-3 inhibitor, was initially tested for the treatment of Alzheimer’s disease. However, a recent report has… 
2019
2019
Tideglusib, a prospective alternative to nonoxynol-9 contraceptive
2017
2017
Correlative Studies Unravelling the Possible Mechanism of Cell Death in Tideglusib-Treated Human Ovarian Teratocarcinoma-Derived PA-1 Cells.
This study aims to unravel the use of GSK-3 inhibitors as viable apoptotic inducers for teratocarcinoma-derived ovarian PA-1… 
Review
2016
Review
2016
Interventions in progressive supranuclear palsy.
2016
2016
A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β
Background New therapeutics are needed for neglected tropical diseases including Human African trypanosomiasis (HAT), a… 
2016
2016
Direct determination of GSK-3β activity and inhibition by UHPLC-UV-vis diode arrays detector (DAD).
2015
2015
Tideglusib, an allosteric inhibitor of Glycogen Synthase Kinase (GSK)‐3β increases Angiogenic activities of Endothelial Cells
The regulation of blood vessel growth is of paramount importance in ischemic cardiovascular and peripheral limb diseases. However… 
2014
2014
Abstract 16804: Tideglusib, a Novel Allosteric Inhibitor of Glycogen Synthase Kinase-3-β Mimics Canonical Wnt Signaling
Rationale: As Glycogen Synthase Kinase-3 (GSK-3)β enzyme regulates β-catenin stability, we addressed the ability of Tideglusib, a… 
Review
2013
Review
2013
A phase II randomized, double-blind, parallel group, 26-week study of GSK-3 inhibitor tideglusib in Alzheimer's disease (ARGO trial)
2011
2011
Structure‐Guided Design of a Highly Selective Glycogen Synthase Kinase‐3β Inhibitor: a Superior Neuroprotective Pyrazolone Showing Antimania Effects
Glycogen synthase kinase 3 (GSK-3), initially identified in the late 1970s as a regulator of glycogen metabolism,[1, 2] is now… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)